Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

CX-4945 . hydrochloride [Silmitasertib . HCl] [1009820-21-6]

Research Use Only
AG-CR1-3629
AdipoGen Life Sciences
CAS Number1009820-21-6
Product group Chemicals
Estimated Purity>98%
Molecular Weight349.8 . 36.5 . x18.0
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    CX-4945 . hydrochloride [Silmitasertib . HCl]
  • Delivery Days Customer
    10
  • CAS Number
    1009820-21-6
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C19H12ClN3O2 . HCl . xH2O
  • Molecular Weight
    349.8 . 36.5 . x18.0
  • Scientific Description
    Chemical. CAS: 1009820-21-6 (free acid). Formula: C19H12ClN3O2 . HCl. MW: 349.8 . 36.5. Synthetic. Orally active, potent and selective ATP-competitive inhibitor of the protein kinase CK2 (IC50=1nM). Anticancer compound. Inhibits proliferation in a panel of cancer cell lines that overexpress CK2. Inhibited migration, blocks survival and induces apoptosis in cancer stem cells, glioblastomas and leukemia cells. Shown to decrease the glucose metabolism in cancer cells. Potent inhibitor of Cdc2-like kinases (Clks) in vitro, consequently interfering with alternative splicing. Potent ATP-competitive inhibitor of DYRK1A (IC50=6.8 nM), involved in neurodegenration-associated diseases. CK2alpha deletion selectively increased M3 muscarinic receptors (M3Rs)-mediated insulin secretion from pancreatic islets. Promoted cAMP-induced thermogenesis in white adipocytes. CK2 inhibition ameliorates diet-induced obesity and insulin resistance in mice in vivo by promoting UCP1-dependent thermogenesis. - Orally active, potent and selective ATP-competitive inhibitor of the protein kinase CK2 (IC50=1nM). Anticancer compound. Inhibits proliferation in a panel of cancer cell lines that overexpress CK2. Inhibited migration, blocks survival and induces apoptosis in cancer stem cells, glioblastomas and leukemia cells. Shown to decrease the glucose metabolism in cancer cells. Potent inhibitor of Cdc2-like kinases (Clks) in vitro, consequently interfering with alternative splicing. Potent ATP-competitive inhibitor of DYRK1A (IC50=6.8nM), DYRK1B (IC50=6.4nM) and DYRK3 (IC50=18nM), involved in neurodegeneration-associated diseases. CK2alpha deletion selectively increased M3 muscarinic receptors (M3Rs)-mediated insulin secretion from pancreatic islets. Promoted cAMP-induced thermogenesis in white adipocytes. CK2 inhibition ameliorates diet-induced obesity and insulin resistance in mice in vivo by promoting UCP1-dependent thermogenesis.
  • SMILES
    ClC1=CC=CC([NH2+]C2=NC3=CC(C(O)=O)=CC=C3C4=C2C=CN=C4)=C1.[Cl-]
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    51202000